Latest News

Chimeric Therapeutics (ASX:CHM) has signed a Letter of Intent with Viral Vector Manufacturing Facility to establish a strategic partnership focused on the development and GMP-grade manufacturing of lentiviral vectors for its cell therapy programs.

Emyria (ASX:EMD) has secured expanded funding support from Medibank Private for patients accessing its treatment-resistant depression and post-traumatic stress disorder programs, marking a significant step in the company’s national growth strategy.

Proteomics International Laboratories (ASX:PIQ) has appointed Vicki Robinson as an independent non-executive director, strengthening its board as the company advances the commercial roll-out of its lead diagnostic products.

The Australian nuclear medicine company has raised its full-year revenue guidance following a solid third quarter marked by 53 per cent year-on-year revenue growth, reimbursement wins in the US, and further expansion of its commercial footprint in Europe.

A pioneering clinical trial led by Neuroscience Research Australia has found that intranasal insulin could offer a promising new treatment for delirium, potentially reducing hospital stays for older patients by several days and addressing a significant gap in care.

Senior Victorian Government representatives will headline flagship events at this year’s AusBiotech International Conference 2025 and AusBiotech Invest Conference 2025 in Melbourne, highlighting the state’s growing leadership in biotechnology and life sciences.

A clinical trial led by Professor Louise Emmett at St Vincent’s Hospital, Sydney, has achieved its primary endpoint, showing that 64Cu-SAR-bisPSMA detects significantly more prostate cancer lesions than the current standard-of-care PSMA PET imaging in men with low PSA levels.

Melbourne nano-biotech Nexsen (ASX:NXN) will debut on the ASX with its world-first biosensing platform that brings lab-grade diagnostics to the point of need.

Adherium (ASX:ADR) has launched an Early Exercise Incentive Offer that rewards eligible optionholders who subscribed under the company’s placement and accelerated non-renounceable entitlement offer.

Adherium (ASX:ADR) has launched an Early Exercise Incentive Offer that rewards eligible optionholders who subscribed under the company’s placement and accelerated non-renounceable entitlement offer.

Medical Developments International (ASX:MVP) used its 2025 AGM to draw a clear line under its rebuild and set out a confident growth agenda.

PYC Therapeutics (ASX:PYC) is advancing its Phelan-McDermid syndrome (PMS) program toward first-in-human studies, reporting non-human primate results that, along with earlier patient-derived neuron data, support progression to the clinic.